Anti-Osteopontin 抗体 (ab11503)
Key features and details
- Goat polyclonal to Osteopontin
- Suitable for: Indirect ELISA, ICC/IF, Blocking, IHC-Fr, WB, Neutralising
- Reacts with: Mouse, Rat
- Isotype: IgG
リコンビナント抗体で、ロット間での高い再現性を実現
- 異なるロット間での安定した再現性
- 容易なスケールアップ
- 評価試験による特異性の確認済み
- 倫理基準に準拠 - アニマル・フリーの生産
製品の概要
-
製品名
Anti-Osteopontin antibody
Osteopontin 一次抗体 製品一覧 -
製品の詳細
Goat polyclonal to Osteopontin -
由来種
Goat -
アプリケーション
適用あり: Indirect ELISA, ICC/IF, Blocking, IHC-Fr, WB, Neutralisingmore details -
種交差性
交差種: Mouse, Rat -
免疫原
Recombinant full length protein (Mouse) expressed in NSO cells.
-
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
バッファー
Constituents: PBS, 5% Trehalose -
Concentration information loading...
-
精製度
Immunogen affinity purified -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab11503の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
Indirect ELISA |
Use at an assay dependent concentration.
|
|
ICC/IF | (1) |
Use at an assay dependent concentration.
|
Blocking |
Use at an assay dependent concentration.
Blocks osteopontin in smooth muscle cell samples. |
|
IHC-Fr |
Use at an assay dependent concentration. PubMed: 17224478
|
|
WB |
Use at an assay dependent concentration.
|
|
Neutralising |
Use at an assay dependent concentration.
The Neutralization Dose50 (ND50) for anti-mouse osteopontin is approximately 1 to 3 µg/ml in the presence of 2 µg/ml of recombinant mouse osteopontin using 293 cells. |
特記事項 |
---|
Indirect ELISA
Use at an assay dependent concentration. |
ICC/IF
Use at an assay dependent concentration. |
Blocking
Use at an assay dependent concentration. Blocks osteopontin in smooth muscle cell samples. |
IHC-Fr
Use at an assay dependent concentration. PubMed: 17224478 |
WB
Use at an assay dependent concentration. |
Neutralising
Use at an assay dependent concentration. The Neutralization Dose50 (ND50) for anti-mouse osteopontin is approximately 1 to 3 µg/ml in the presence of 2 µg/ml of recombinant mouse osteopontin using 293 cells. |
ターゲット情報
-
機能
Binds tightly to hydroxyapatite. Appears to form an integral part of the mineralized matrix. Probably important to cell-matrix interaction.
Acts as a cytokine involved in enhancing production of interferon-gamma and interleukin-12 and reducing production of interleukin-10 and is essential in the pathway that leads to type I immunity. -
組織特異性
Bone. Found in plasma. -
配列類似性
Belongs to the osteopontin family. -
翻訳後修飾
Extensively phosphorylated on clustered serine residues.
N- and O-glycosylated.
Phosphorylation sites are present in the extracelllular medium. -
細胞内局在
Secreted. - Information by UniProt
-
参照データベース
- Entrez Gene: 20750 Mouse
- Entrez Gene: 25353 Rat
- SwissProt: P10923 Mouse
- SwissProt: P08721 Rat
- Unigene: 288474 Mouse
- Unigene: 8871 Rat
-
別名
- BNSP antibody
- Bone sialoprotein 1 antibody
- Bone sialoprotein I antibody
see all
プロトコール
データシートおよび資料
-
Datasheet download
参考文献 (10)
ab11503 は 10 報の論文で使用されています。
- Xin D et al. MSCs-extracellular vesicles attenuated neuroinflammation, synapse damage and microglial phagocytosis after hypoxia-ischemia injury by preventing osteopontin expression. Pharmacol Res 164:105322 (2021). PubMed: 33279596
- Giopanou I et al. Osteopontin drives KRAS-mutant lung adenocarcinoma. Carcinogenesis 41:1134-1144 (2020). PubMed: 31740923
- Hou YC et al. Tailoring of cardiovascular stent material surface by immobilizing exosomes for better pro-endothelialization function. Colloids Surf B Biointerfaces 189:110831 (2020). PubMed: 32058252
- Sharon Y et al. Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer. Cancer Res 75:963-73 (2015). IHC-P ; Mouse . PubMed: 25600648
- Shibasaki M et al. Pitavastatin Reduces Inflammation in Atherosclerotic Plaques in Apolipoprotein E-Deficient Mice with Late Stage Renal Disease. PLoS One 10:e0138047 (2015). PubMed: 26367531
- Ge X et al. Evodiamine Attenuates PDGF-BB-Induced Migration of Rat Vascular Smooth Muscle Cells through Activating PPAR?. Int J Mol Sci 16:28180-93 (2015). PubMed: 26703570
- Deangelis T et al. Growth of V-SRC-transformed cells in serum-free medium through the induction of growth factors. J Cell Physiol : (2012). PubMed: 23254450
- Redding KM et al. Transgenic mice expressing an intracellular fluorescent fusion of angiotensin II demonstrate renal thrombotic microangiopathy and elevated blood pressure. Am J Physiol Heart Circ Physiol 298:H1807-18 (2010). WB ; Mouse . PubMed: 20363893
- Yang X et al. Bone morphogenic protein 2 induces Runx2 and osteopontin expression in human aortic valve interstitial cells: role of Smad1 and extracellular signal-regulated kinase 1/2. J Thorac Cardiovasc Surg 138:1008-15 (2009). PubMed: 19664780
- Aikawa E et al. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 115:377-86 (2007). IHC-Fr ; Mouse . PubMed: 17224478